What is BridgeBio Pharma?
BridgeBio Pharma, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the discovery, creation, and delivery of precision medicines. The company focuses on genetic conditions and oncology, utilizing a decentralized model that allows for rapid development of high-potential therapeutic candidates. Its current portfolio includes advanced programs such as AG10, a next-generation TTR stabilizer, and various gene transfer initiatives aimed at addressing congenital adrenal hyperplasia. By targeting the underlying molecular drivers of disease, BridgeBio has established a formidable presence in the life sciences industry, bridging the gap between academic research and commercial-scale patient care.
How much funding has BridgeBio Pharma raised?
BridgeBio Pharma has raised a total of $3B across 6 funding rounds:
Series C
$135M
Other Financing Round
$299.2M
Debt
$475M
Debt
$750M
Other Financing Round
$300M
Stock/Share Issuance
$1B
Series C (2017): $135M with participation from Aisling Capital, Perceptive Advisors, and Cormorant Asset Management
Other Financing Round (2019): $299.2M led by Hercules Capital, Cormorant Capital, Aisling Capital, AIG, Perceptive Advisors, and Steamboat Ventures
Debt (2020): $475M, investors not publicly disclosed
Debt (2021): $750M, investors not publicly disclosed
Other Financing Round (2025): $300M backed by HealthCare Royalty Management and Blue Owl
Stock/Share Issuance (2026): $1B with participation from Sixth Street and HealthCare Royalty Management
Key Investors in BridgeBio Pharma
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies.
Perceptive Advisors
Founded in 1999, Perceptive Advisors is an investment firm managing significant assets focused on funding innovative healthcare and life sciences technologies.
HealthCare Royalty Management
HealthCare Royalty is a specialized investment organization providing capital solutions to biopharmaceutical companies through royalty interests and tailored financing.
What's next for BridgeBio Pharma?
With the recent capital injection, BridgeBio Pharma is set to prioritize the execution of its Phase 3 clinical trials and the potential commercialization of its lead assets. The strategic focus will likely shift toward scaling manufacturing capabilities and expanding global regulatory submissions. As the company transitions further into a commercial-stage powerhouse, the management team is expected to leverage these resources to de-risk its pipeline and pursue long-term value creation for stakeholders. The integration of non-dilutive financing and equity-based support provides the necessary runway to sustain innovation through the next critical phases of clinical development and market entry.
See full BridgeBio Pharma company page
